Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Without an IPO, Rib-X Raises $67.5 Million In Venture Funding

This article was originally published in The Pink Sheet Daily

Executive Summary

Rib-X will use the venture infusion to try to replicate Phase IIb data that indicated superiority to vancomycin for its broad-spectrum fluoroquinolone antibiotic.

You may also be interested in...



Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics

Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.

Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value

Drug developers face enormous regulatory and commercial hurdles in the antibiotics market, but industry is looking to challenge the current business model with new premium-priced drugs that deliver compelling pharmaco-economic benefits over generics.

The Future Of Private Biotech Investment: A Q&A With Jonathan Leff

Long-time Warburg Pincus investor Jonathan Leff is making a move to Deerfield Management. He tells “The Pink Sheet” about his plans and contemplates what’s next for investment in private biotechs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel